Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001455244-11-000019
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-04-05 17:18:45
Reporting Period:
2011-04-01
Filing Date:
2011-04-05
Accepted Time:
2011-04-05 17:18:45
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
72444 Nabi Biopharmaceuticals NABI Biological Products, (No Disgnostic Substances) (2836) 591212264
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1459477 W. Matthew Kalnik 8610 Fernwood Road
Bethesda MD 20817
Svp Strategic Plan. & Bus. Ops No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2011-04-01 6,300 $5.80 41,050 No 4 S Direct
Common Stock Acquisiton 2011-04-01 30,000 $0.00 71,050 No 4 A Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 A Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Acquisiton 2011-04-01 75,000 $0.00 75,000 $5.81
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
75,000 2018-04-01 No 4 A Direct
Footnotes
  1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
  2. Restricted Stock which vests in four equal annual installments beginning on April 1, 2012.
  3. This Option will become exercisable in four equal annual installments beginning on April 1, 2012.